Breast Cancer in Indian Women: Genetic Risk Factors and Predictive Biomarkers

Abstract

Breast cancer is the most common cancer among Indian women with a significant increase in incidence in young women. To identify risk factors for breast cancer in young women, study of BRCA1 and BRCA2 germ line mutations was done in a cohort of 204 Indian breast cancer patients. The study showed a total of 18 mutations in 2.94% of the tested patients, 44% BRCA1 and 78% BRCA2 mutations were found unique to the Indian population. Association of low penetrance genes mainly CYP17, VDR gene and AR-CAG repeat polymorphisms with breast cancer risk showed CYP17 A2 and VDR Poly-A L as high risk alleles, the risk of developing breast cancer among women carrying three high-risk alleles is 4.68 (95% confidence interval [CI]: 0.77–28.0; p for trend = 0.10) compared with women carrying none. CYP17 A2 allele was also found associated with development of breast cancer at young age and can also serve as a target for therapy. Betel quid chewing has been found as a significant and independent risk factor for developing breast cancer in North East Indian women which induces genetic alterations leading to breast carcinogenesis. Studies to assess the predictive role of various tumor markers showed that expression of p-glycoprotein in pretreatment biopsy predicts a poor clinical response to neoadjuvant chemotherapy (NACT) in patients having locally advanced breast cancer. The chemotherapy-induced toxicity (vomiting and alopecia) correlated significantly with clinical and immunohistochemical response (reduction in bcl2/bax ratio) and were found to be a cost-effective and reliable predictor of response to NACT. Androgen receptor (AR) has been identified as independent predictive marker for response to NACT in locally advanced breast cancer cases and can serve as novel therapeutic target for triple negative breast cancers.

Keywords

breast cancer - genetic risk factors - predictive biomarkers

• References

• 1 National Cancer Registry Programme. Three Year Report of Population Based Cancer Registries 2012–2014. Bangalore: Indian Council of Medical Research (ICMR); 2016
• 2 Murthy NS, Chaudhry K, Nadayil D, Agarwal UK, Saxena S. Changing trends in incidence of breast cancer: Indian scenario. Indian J. Cancer 2009; 46 (01) 73-74
• 3 Saxena S, Rekhi B, Bansal A, Bagga A, Chintamani. Murthy NS. Clinico-morphological patterns of breast cancer including family history in a New Delhi hospital, India–a cross-sectional study. World J Surg Oncol 2005; 3: 67
• 4 Hall JM, Lee MK, Newman B. et al. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990; 250 (4988): 1684-1689
• 5 Wooster R, Neuhausen SL, Mangion J. et al. Localization of a breast cancer susceptibility gene, BRCA2, to chromosome 13q12-13. Science 1994; 265 (5181): 2088-2090
• 6 Miki Y, Swensen J, Shattuck-Eidens D, et al; BRCA SG. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 1994; 266 (5182): 66-71
• 7 Wooster R, Bignell G, Lancaster J. et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378 (6559): 789-792
• 8 Tavtigian SV, Simard J, Rommens J. et al. The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet 1996; 12 (03) 333-337
• 9 Saxena S, Chakraborty A, Kaushal M. et al. Contribution of germline BRCA1 and BRCA2 sequence alterations to breast cancer in Northern India. BMC Med Genet 2006; 7: 75
• 10 Saxena S, Szabo CI, Chopin S. et al. BRCA1 and BRCA2 in Indian breast cancer patients. Hum Mutat 2002; 20 (06) 473-474
• 11 Lupulescu A. Estrogen use and cancer incidence: a review. Cancer Invest 1995; 13 (03) 287-295
• 12 Pike MC, Pearce CL, Wu AH. Prevention of cancers of the breast, endometrium and ovary. Oncogene 2004; 23 (38) 6379-6391
• 13 Feigelson HS, Henderson BE. Estrogens and breast cancer. Carcinogenesis 1996; 17 (11) 2279-2284
• 14 Hanukoglu I. Steroidogenic enzymes: structure, function, and role in regulation of steroid hormone biosynthesis. J Steroid Biochem Mol Biol 1992; 43 (08) 779-804
• 15 Brentano ST, Picado-Leonard J, Mellon SH, Moore CC, Miller WL. Tissue-specific, cyclic adenosine 3′,5′-monophosphate-induced, and phorbol ester-repressed transcription from the human P450c17 promoter in mouse cells. Mol Endocrinol 1990; 4 (12) 1972-1979
• 16 Carey AH, Waterworth D, Patel K. et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994; 3 (10) 1873-1876
• 17 Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytochrome P450c17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998; 58 (04) 585-587
• 18 Chakraborty A, Murthy NS, Chintamani C. et al. CYP17 gene polymorphism and its association with high-risk north Indian breast cancer patients. J Hum Genet 2007; 52 (02) 159-165
• 19 Colston KW, Chander SK, Mackay AG, Coombes RC. Effects of synthetic vitamin D analogues on breast cancer cell proliferation in vivo and in vitro. Biochem Pharmacol 1992; 44 (04) 693-702
• 20 Hansen CM, Frandsen TL, Brünner N, Binderup L. 1 α, 25-dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 1994; 12 (03) 195-202
• 21 James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol 1996; 58 (04) 395-401
• 22 Chakraborty A, Mishra AK, Soni A. et al. Vitamin D receptor gene polymorphism(s) and breast cancer risk in north Indians. Cancer Detect Prev 2009; 32 (05) [phone]
• 23 Nicolás Díaz-ChicoB, Germán RodríguezF, González A. et al. Androgens and androgen receptors in breast cancer. J Steroid Biochem Mol Biol 2007; 105 (01) (05) 1-15
• 24 Gonzalez LO, Corte MD, Vazquez J. et al. Androgen receptor expresion in breast cancer: relationship with clinicopathological characteristics of the tumors, prognosis, and expression of metalloproteases and their inhibitors. BMC Cancer 2008; 8: 149
• 25 Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res 1994; 22 (15) 3181-3186
• 26 Mittal RD, Mishra D, Mandhani AK. Role of an androgen receptor gene polymorphism in development of hormone refractory prostate cancer in Indian population. Asian Pac J Cancer Prev 2007; 8 (02) 275-278
• 27 Mishra D, Thangaraj K, Mandhani A, Kumar A, Mittal R. Is reduced CAG repeat length in androgen receptor gene associated with risk of prostate cancer in Indian population?. Clin Genet 2005; 68 (01) 55-60
• 28 Chintamani. Kulshreshtha P, Chakraborty A. et al. Androgen receptor status predicts response to chemotherapy, not risk of breast cancer in Indian women. World J Surg Oncol 2010; 8: 64
• 29 Terry PD, Rohan TE. Cigarette smoking and the risk of breast cancer in women: a review of the literature. Cancer Epidemiol Biomarkers Prev 2002; 11 (10) Pt 1): 953-971
• 30 Mudur G. India has some of the highest cancer rates in the world. BMJ 2005; 330 (7485): 215
• 31 Williams JA, Phillips DH. Mammary expression of xenobiotic metabolizing enzymes and their potential role in breast cancer. Cancer Res 2000; 60 (17) 4667-4677
• 32 Boffetta P, Hecht S, Gray N, Gupta P, Straif K. Smokeless tobacco and cancer. Lancet Oncol 2008; 9 (07) 667-675
• 33 Lash TL, Bradbury BD, Wilk JB, Aschengrau A. A case-only analysis of the interaction between N-acetyltransferase 2 haplotypes and tobacco smoke in breast cancer etiology. Breast Cancer Res 2005; 7 (03) R385-R393
• 34 Anantharaman D, Chaubal PM, Kannan S, Bhisey RA, Mahimkar MB. Susceptibility to oral cancer by genetic polymorphisms at CYP1A1, GSTM1 and GSTT1 loci among Indians: tobacco exposure as a risk modulator. Carcinogenesis 2007; 28 (07) 1455-1462
• 35 Kaushal M, Mishra AK, Raju BS. et al. Betel quid chewing as an environmental risk factor for breast cancer. Mutat Res 2010; 703 (02) 143-148
• 36 Narayan S, Jaiswal AS, Kang D, Srivastava P, Das GM, Gairola CG. Cigarette smoke condensate-induced transformation of normal human breast epithelial cells in vitro. Oncogene 2004; 23 (35) 5880-5889
• 37 Nair U, Bartsch H, Nair J. Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. Mutagenesis 2004; 19 (04) 251-262
• 38 Luo LZ, Werner KM, Gollin SM, Saunders WS. Cigarette smoke induces anaphase bridges and genomic imbalances in normal cells. Mutat Res 2004; 554 (01) [phone]
• 39 Herzog CR, Desai D, Amin S. Array CGH analysis reveals chromosomal aberrations in mouse lung adenocarcinomas induced by the human lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone. Biochem Biophys Res Commun 2006; 341 (03) 856-863
• 40 Singh B, Wreesmann VB, Pfister D. et al. Chromosomal aberrations in patients with head and neck squamous cell carcinoma do not vary based on severity of tobacco/alcohol exposure. BMC Genet 2002; 3: 22
• 41 Kaushal M, Mishra AK, Sharma J. et al. Genomic alterations in breast cancer patients in betel quid and non betel quid chewers. PLoS One 2012; 7 (08) e43789
• 42 Deo SV, Bhutani M, Shukla NK, Raina V, Rath GK, Purkayasth J. Randomized trial comparing neo-adjuvant versus adjuvant chemotherapy in operable locally advanced breast cancer (T4b N0-2 M0). J Surg Oncol 2003; 84 (04) 192-197
• 43 Charfare H, Limongelli S, Purushotham AD. Neoadjuvant chemotherapy in breast cancer. Br J Surg 2005; 92 (01) 14-23
• 44 Heys SD, Chaturvedi S. Primary chemotherapy in breast cancer: The beginning of the end or the end of the beginning for the surgical oncologist?. World J Surg Oncol 2003; 1 (01) 14
• 45 Gerlach JH, Kartner N, Bell DR, Ling V. Multidrug resistance. Cancer Surv 1986; 5 (01) 25-46
• 46 Schneider J, Bak M, Efferth T, Kaufmann M, Mattern J, Volm M. P-glycoprotein expression in treated and untreated human breast cancer. Br J Cancer 1989; 60 (06) 815-818
• 47 Chintamani. Singh JP, Mittal MK. et al. Role of p-glycoprotein expression in predicting response to neoadjuvant chemotherapy in breast cancer–a prospective clinical study. World J Surg Oncol 2005; 3: 61
• 48 Ellis PA, Smith IE, Detre S. et al. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 1998; 48 (02) 107-116
• 49 Kerr JF, Winterford CM, Harmon BV. Apoptosis. Its significance in cancer and cancer therapy. Cancer 1994; 73 (08) 2013-2026
• 50 Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L, Silingardi V. Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat 1997; 44 (03) 185-192
• 51 Chintamani SV, Singhal V, Singh JP, Lyall A, Saxena S, Bansal A. Is drug-induced toxicity a good predictor of response to neo-adjuvant chemotherapy in patients with breast cancer?–a prospective clinical study. BMC Cancer 2004; 4: 48
• 52 Edelmann W, Yang K, Umar A. et al. Mutation in the mismatch repair gene Msh6 causes cancer susceptibility. Cell 1997; 91 (04) 467-477
• 53 Yamada M, O'Regan E, Brown R, Karran P. Selective recognition of a cisplatin-DNA adduct by human mismatch repair proteins. Nucleic Acids Res 1997; 25 (03) 491-496
• 54 Fink D, Aebi S, Howell SB. The role of DNA mismatch repair in drug resistance. Clin Cancer Res 1998; 4 (01) 1-6
• 55 Chiaravalli AM, Furlan D, Facco C. et al. Immunohistochemical pattern of hMSH2/hMLH1 in familial and sporadic colorectal, gastric, endometrial and ovarian carcinomas with instability in microsatellite sequences. Virchows Arch 2001; 438 (01) 39-48
• 56 Shi WF, Leong M, Cho E. et al. Repressive effects of resveratrol on androgen receptor transcriptional activity. PLoS One 2009; 4 (10) e7398
• 57 Brinkmann AO, Trapman J. Prostate cancer schemes for androgen escape. Nat Med 2000; 6 (06) 628-629
• 58 Shang Y, Myers M, Brown M. Formation of the androgen receptor transcription complex. Mol Cell 2002; 9 (03) 601-610
• 59 Coffey K, Robson CN. Regulation of the androgen receptor by post-translational modifications. J Endocrinol 2012; 215 (02) 221-237
• 60 Doane AS, Danso M, Lal P. et al. An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene 2006; 25 (28) 3994-4008
• 61 Hickey TE, Robinson JL, Carroll JS, Tilley WD. Minireview: The androgen receptor in breast tissues: growth inhibitor, tumor suppressor, oncogene?. Mol Endocrinol 2012; 26 (08) 1252-1267
• 62 Mishra AK, Agrawal U, Negi S. et al. Expression of androgen receptor in breast cancer & its correlation with other steroid receptors & growth factors. Indian J Med Res 2012; 135 (06) 843-852
• 63 Singh LC, Chakraborty A, Mishra AK. et al. Study on predictive role of AR and EGFR family genes with response to neoadjuvant chemotherapy in locally advanced breast cancer in Indian women. Med Oncol 2012; 29 (02) 539-546
• 64 Mehta J, Asthana S, Mandal CC, Saxena S. A molecular analysis provides novel insights into androgen receptor signalling in breast cancer. PLoS One 2015; 10 (03) e0120622